Lexaria Extends Material Transfer Agreement with PharmaCO
November 12, 2025 — Kelowna, British Columbia — Leads & Copy — Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) has extended its Material Transfer Agreement (MTA) with a pharmaceutical company (PharmaCO) to April 30, 2026.
The original agreement, established on September 4, 2024, focuses on evaluating Lexaria’s DehydraTECH™ technology in a pre-clinical setting.
The extension accommodates the time needed for PharmaCO to receive and review the full dataset from Lexaria’s Australian study. Following this review, further information will be provided.
The extended agreement allows both parties to continue their relationship under the MTA, maintain the temporary exclusive license, and consider further strategic planning discussions with PharmaCO’s human clinical development team.
Earlier in 2025, initial pre-clinical studies covered by the MTA, which examined pharmacokinetics in animals, were completed. PharmaCO expressed interest in reviewing safety, pharmacokinetic, and efficacy data from Lexaria’s independent Australian human clinical study GLP-1-H24-4.
This study is currently undergoing full sample and data analyses. Lexaria anticipates releasing the final results of the Australian study before the end of the fourth quarter of 2025.
DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology. It is designed to improve drug absorption into the bloodstream through oral delivery.
DehydraTECH™ has shown the ability to increase bio-absorption, reduce side effects, and enhance the delivery of some drugs across the blood-brain barrier.
Lexaria operates a licensed in-house research laboratory and holds a portfolio of 54 granted patents, with additional patents pending worldwide.
Caution Regarding Forward-Looking Statements: This press release contains forward-looking statements involving risks and uncertainties. Actual results may differ materially due to various factors, including market conditions, regulatory approvals, competition, and scientific discovery. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. These statements have not been evaluated by the FDA, and Lexaria products are not intended to diagnose, treat, cure, or prevent any disease.
George Jurcic – Head of Investor Relations, ir@lexariabioscience.com, Phone: 250-765-6424, ext 202
Source: Lexaria Bioscience Corp.
Share this story:
